Close Menu

Waters

The company posted Q2 revenues of $520.0 million, down 13 percent from $599.2 million in Q2 2019, but above analysts' average estimate of $496.9 million.

The firm's predicted Q2 revenues of $517 million to $523 million beat expectations as former MilliporeSigma CEO Udit Batra becomes president and CEO.

The index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in the first half of the year.

The GenomeWeb Index rose more than 2 percent in June, but the increase was subdued compared to the index's 9 percent climb in May and 18 percent hike in April.

While there were a few new mass spectrometry instrument introductions, vendors focused primarily on software and sample separation advances.

Waters posted revenues of $464.9 million for the quarter as the SARS-CoV-2 pandemic drove a drop in sales globally, including a 45 percent decline in China.

Revenues during the quarter were $716.3 million, beating Wall Street estimates, while full year 2019 revenues totaled $2.41 billion.

Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.

With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.